Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2013

View Archived Issues

Subcutaneous grass pollen monomeric carbamylated allergoid tested in allergic rhinoconjunctivitis

Changes in FXIII observed in patients with myocardial infarction

Matrix metalloproteinase-10 levels increased in patients with peripheral artery disease

New ACC-beta inhibitors synthesized by Boehringer Ingelheim

Ironwood Pharmaceuticals prepares new sGC activators

BioDiem's liver disease vaccine program achieves proof of principle

Roche launches Elecsys ProGRP test to diagnose small cell lung cancer

Medigen Biotechnology provides update on phase III PATRON trial

BioCryst completes phase I trial of BCX-4161

Xoma provides update on development program for gevokizumab

Bio-Path begins development of liposomal GRB2 for two breast cancer indications

Merrimack begins patient enrollment in phase II trial in advanced gastroesophageal cancers

MBio Diagnostics receives NIH grant to continue development of POC HIV diagnostic device

Researchers disclose new agents for sickle cell disease and other disorders

Agios Pharmaceuticals divulges new IDH2 inhibitors for cancer

Spinifex Pharmaceuticals synthesizes novel AT2 receptor antagonists

Alzheimer's disease vaccine vanutide evaluated in Japanese patients in phase II study

Janssen R&D patents novel agents for HBV infection

AB Science receives funding to develop therapy for Alzheimer's disease

Galapagos earns milestone in osteoarthritis alliance with Servier

New sodium channel blockers presented by Pfizer

Phase II data reported for BMS-927711 in migraine

Prana completes phase II trial of lead candidate in Huntington's disease

Atterocor commences first-in-human trial of ATR-101 in advanced adrenocortical carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...